Figure 3
![Figure 3. Validation of antiangiogenic drugs with hAR assays. (A) hARs treated with antiangiogenic drugs. Quantification of angiogenic outgrowth at 15 days of culture in EGM-2. hARs treated with indicated concentrations of Sunitinib, SU5416, PI-103, Avastin, and anti-VEGF Ab. For Combretastatin, a vascular-disrupting agent, the treatment started at day 19 (shown in supplemental Figure 6B). Values shown are box-and-whisker plots, normalized to the median of DMSO or control IgG-treated hARs, of 3 independent experiments, each from 6 different umbilical cords (*P < .05 vs DMSO or control [ctr] IgG hARs; **P < .01; ***P < .001). (B) Evaluation of IC50 of antiangiogenic drugs on human and mAR assays. Nonlinear regression R2 > 0.7.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/121/21/10.1182_blood-2012-08-452292/4/e129f3.jpeg?Expires=1724230827&Signature=4Fjsuc9ORbkIidAIXXDkOdGbMHhNqmcLGTSdQ-73ltRJJ8MZHA-tx4-x6J9mMh5uQH4aFMwzFaCIxunjJx~ZPajRkuxCOq79CHW6WSKaii0Uh2xXFI1o3bpJJrcmMdqJWdRieKjFngeQnV0NnPPWHuF2u1wI0RCslg5D17mb9I4Fum32cfuNZ-H~o~cPJRNfzv2i4OtMt4XSKnItAS7Dd3yr~EZi~m~boyZ9Pt23nq19B0P80Z27DhXgnf93uUCpQtO40cijEGFoTEWbWIfDhh~7LNcZ9Dgcs7IB9iOP5JQCEIx1cSCX08G3WJm~GZqna4xi7vFvi2Qgd3UpWOOl~Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Validation of antiangiogenic drugs with hAR assays. (A) hARs treated with antiangiogenic drugs. Quantification of angiogenic outgrowth at 15 days of culture in EGM-2. hARs treated with indicated concentrations of Sunitinib, SU5416, PI-103, Avastin, and anti-VEGF Ab. For Combretastatin, a vascular-disrupting agent, the treatment started at day 19 (shown in supplemental Figure 6B). Values shown are box-and-whisker plots, normalized to the median of DMSO or control IgG-treated hARs, of 3 independent experiments, each from 6 different umbilical cords (*P < .05 vs DMSO or control [ctr] IgG hARs; **P < .01; ***P < .001). (B) Evaluation of IC50 of antiangiogenic drugs on human and mAR assays. Nonlinear regression R2 > 0.7.
